Abgenics is developing libraries of camelid antibodies against the most common cancers that occur in India. The libraries are biopanned using the phage display system against patient cancer tissues to obtain the CaMabs against know as well as novel targets. Abgenics has also developed the capability to identify the target of the individual antibodies using proteomic techniques.
We plan to isolate neutralizing CaMabs from the library and use a cocktail of antibodies against multiple targets in the cancerous cells for a more effective therapy. These antibodies can also be used to direct novel drugs to the site of action and also be tagged with molecules for imaging or diagnostic applications.